✦ LIBER ✦

Central nervous system toxicity of high-dose systemic cytosine arabinoside

✍ Scribed by Hillard M. Lazarus; Roger H. Herzig; David J. Fishman; Geoffrey P. Herzig; Gordon L. Phillips; Uros Roessmann

Publisher: John Wiley and Sons
Year: 1981
Tongue: English
Weight: 624 KB
Volume: 48
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19811215)48:12<2577::aid-cncr2820481207>3.0.co;2-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Central nervous system toxicity of high-

Central nervous system toxicity of high-dose cytosine arabinoside

✍ Grossman, L. ;Baker, M. A. ;Sutton, D. M. C. ;Deck, J. H. N. 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 502 KB

Treatment of central nervous system leuk

Treatment of central nervous system leukemia with intrathecal cytosine arabinoside

✍ Pierre R. Band; James F. Holland; Jean Bernard; Marise Weil; Michael Walker; Dav 📂 Article 📅 1973 🏛 John Wiley and Sons 🌐 English ⚖ 341 KB 👁 2 views

Central nervous system toxicity associat

Central nervous system toxicity associated with weekly low-dose methotrexate treatment

✍ Richard Wernick; David L. Smith 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 553 KB

Successful treatment of recurrent primar

Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate

✍ Thomas Ervin; George P. Canellos 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB 👁 2 views

NOA-03 trial of high-dose methotrexate i

NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: Final report

✍ Ulrich Herrlinger; Wilhelm Küker; Martin Uhl; Hans-Peter Blaicher; Hans-Otto Kar 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 1 views

The role of systemic high-dose cytarabin

The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia clinical results in 46 patients

✍ Enrica Morra; Mario Lazzarino; Ercole Brusamolino; Guido Pagnucco; Carlo Castagn 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 701 KB

Background. Given the good penetration of systemic high-dose cytarabine (HDara-C) into the cerebrospinal fluid (CSF), this approach was used to treat patients with central nervous system (CNS) leukemia, either isolated or with concurrent extraneurologic disease (END). Methods. From 1983 to 1991,46